Catalio Capital

ActiveVenture Capital

Website LinkedIn X

Updated: Jan 22, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Nov 1, 2025	Azalea Therapeutics	$65.0M Series A	—	Third Rock Ventures, Vivo Capital
Dec 1, 2024	Bluenote Health	$10.0M Venture Round	—	468 Capital, 7wire Ventures, Andreessen Horowitz, Artichoke Capital, Cherubic Ventures, Dragonfly Capital Partners, Electric Capital, Lux Capital, Paradigm, Placeholder, Refactor Capital, Robot Ventures, Rocketship.vc, Sequoia Capital, Sherpalo Ventures, The Hit Forge, XFactor Ventures, Ameet Patel, Amjad Masad, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Baris Gultekin, Biz Stone, Dylan Field, Gokul Rajaram, Josh Elman, Kunal Shah, Varsha Rao
Dec 1, 2024	Nuvig Therapeutics	$160.0M Series B	—	MPM Capital, Polaris Partners
Sep 1, 2024	Nomic	$42.0M Series B	—	2048 Ventures, AVANT BIO, Dimension Capital, Jenny Fielding, Scott Hartley, Trajectory Ventures, Mei Z.
Apr 1, 2024	Perplexity	$63.0M Series C	—	20VC, 2.12 Angels, 355 Capital, Kevin Hartz, Accomplice VC, Ambush Capital, AME Cloud Ventures, Andreessen Horowitz, Angel investor, Asylum Ventures, C2 Investment, Cedar Capital Group, Costanoa Ventures, DTCP, E1 Ventures, EQT Ventures, Family Office, Felicis Ventures, Fifty Years, Floodgate, Founders Fund, GSV Acceleration, Hanabi Capital, Hardware Club, Haun Ventures, Heroic Ventures, HOF Capital, Infinite Niches, Inflection, Insight Partners, Jefferies, Kindred Ventures, Kleiner Perkins, Lightspeed Venture Partners, Lux Capital, Matchstick Ventures, Maven Ventures, Mustard Seed, NFX, Northzone, Race Capital, Rakuten Ventures, Refactor Capital, Sherpalo Ventures, Spark Capital, Susa Ventures, The Hit Forge, Thrive Capital, Uncork Capital, Union Square Ventures, UpHonest Capital, Wayra UK, Y Combinator, Aaron Harris, Amjad Masad, Andy Coravos, Anne Wojcicki, Arash Ferdowsi, Balaji Srinivasan, Charlie Songhurst, Chintan Patel, Fidji Simo, Jared Sleeper, Jonathan Lenson, Justin Kitch, Jutta Steiner, Mike Vernal, Mike Volpe, Miras Mami, Peter Sonsini, Sahin Boydas, Scott Belsky, Varsha Rao
Apr 1, 2024	Rubedo Life Sciences	$40.0M Series A	—	7percent Ventures, Ahren Innovation Capital, Alumni Ventures, Gaingels, Khosla Ventures, MarsBio, Moonstone Venture Capital, Presight Capital, Refactor Capital, SOSV, The House Fund, The Longevity Fund, Tiger Global Management, TLV Partners, Tuesday Capital, Amjad Masad, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Dan Ciporin, Dylan Field, Fidji Simo, Justin Mateen, Rich Miner, Varsha Rao
Mar 1, 2024	LiveKit	$22.0M Series A	—	Afore Capital, Andreessen Horowitz, Banana Capital, Dan Cahana, Glenn Solomon, Preston-Werner Ventures, Refactor Capital, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Dylan Field, Fidji Simo, Varsha Rao, Guillermo Rauch
Mar 1, 2024	Clasp Therapeutics	$150.0M Series A	—	Third Rock Ventures, Vivo Capital
Feb 1, 2024	Ezra AI	$21.0M Series B	—	Antler, FirstMark Capital, Refactor Capital, Silence, Amjad Masad, Andy Coravos, Balaji Srinivasan, Dylan Field, Fidji Simo, Gokul Rajaram, Manik Gupta, Miki Kuusi, Varsha Rao
Feb 1, 2024	Stilla Technologies	$27.0M Series C	—	EQT Life Sciences, Illumina Ventures, Kurma Partners, Soffinova Partners
Feb 1, 2024	NextPoint Therapeutics	$43.0M Series B	—	ARCH Venture Partners, Atlas Venture, MPM Capital, Polaris Partners
Dec 1, 2023	Orchid	$12.0M Seed	—	Kevin Hartz, Alchemy Ventures, Andreessen Horowitz, Bessemer Venture Partners, CRV, Felicis Ventures, Founder Collective, Goat Capital, Greenoaks Capital, Haun Ventures, Infinite Niches, Infinity Ventures Crypto, Jetstream, Khosla Ventures, Lightspeed Venture Partners, N49P Ventures, NKM Capital, Glenn Solomon, Openview Venture Partners, Polychain Capital, Redpoint Ventures, Refactor Capital, RTP Global, TCV, The Hit Forge, Weekend Fund, WorkLife Ventures, Amjad Masad, Andy Coravos, Anne Wojcicki, Balaji Srinivasan, Barr Moses, Dylan Field, Fidji Simo, Gokul Rajaram, Immad Akhund, Julia Hartz, Varsha Rao, Vivek Patel
Feb 1, 2023	Thymmune Therapeutics	$7.0M Seed	—	Flagship Ventures, Third Rock Ventures
Nov 1, 2022	Haystack Oncology	$56.0M Series A	—	Andreessen Horowitz, Dimension Capital, VZVC, Mei Z.
Sep 1, 2022	Rootine	$10.0M Series A	—	Refactor Capital, Amjad Masad, Anne Wojcicki, Balaji Srinivasan, Dylan Field, Fidji Simo, Varsha Rao
Aug 1, 2022	VitaDAO	$500K Seed	—	2xN, Andreessen Horowitz, Angel investor, Haun Ventures, Highbury Group, Pfizer Venture Investments, Ulu Ventures, What If Ventures, WndrCo LLC
Jul 1, 2022	Apriori Bio	$50.0M Series A	—	Flagship Pioneering, Flagship Ventures
Jul 1, 2022	CAMP4 Therapeutics	$100.0M Series B	—	2xN, 5AM Ventures, Aisling Capital, Andreessen Horowitz, Angel investor, Haun Ventures, Highbury Group, Northpond Ventures, OrbiMed, Ulu Ventures, What If Ventures, WndrCo LLC
Jun 1, 2022	Anagenex	$30.0M Series A	—	ARCH Venture Partners, Kiersten Stead, Dimension Capital
May 1, 2022	Osmind	$40.0M Series B	—	11, 2xN, Abstract Ventures, Kevin Hartz, Accel, Addition, Alumni Ventures, Amplo, Andreessen Horowitz, Angel investor, Atomic, Audrey Capital, Avalon Ventures, Craft Ventures, DFJ Growth, Dimension Capital, Dreamers VC, DST Global, Electric Capital, Founder Collective, Founders Fund, General Catalyst, Haun Ventures, Highbury Group, IA Ventures, ICONIQ Capital, In-Q-Tel, Interlock Partners, Jetstream, Khosla Ventures, LGF, Long Journey Ventures, Lux Capital, Maveron, Menlo Ventures, NewFund, Paradox Capital, Primer Sazze Partners, Quiet Capital, Sequoia Capital, Sonder Capital, Sound Ventures, Susa Ventures, The Hit Forge, Thirty Five Ventures, Ulu Ventures, Union Square Ventures, What If Ventures, WndrCo LLC, XStarPartners, Y Combinator, ZhenFund, Adrian Aoun, Amjad Masad, Anna Yuan, Anne Wojcicki, Brad Bao, Bradley Horowitz, David Mytton, Eric Ries, Guillaume Lestrade, Jared Leto, Jeffrey Lee, Joshua Reeves, Julie Zhuo, Kevin Weil, Marc Benioff, Mike Krieger, Odell Beckham Jr., Oleg Rogynskyy, Omar El-Ayat, Othman Laraki, Sam Altman, Tobias Lutke, Tony Xu, Young Song
Apr 1, 2022	Octant Bio	$80.0M Series B	—	Andreessen Horowitz, Angel investor, EQT Life Sciences, GSR Ventures, Illumina Ventures, Insight Partners, Kleiner Perkins, Kurma Partners, Polaris Partners, Polygon, Soffinova Partners, Tomahawk.VC, What If Ventures, Balaji Srinivasan
Apr 1, 2022	Pheast Therapeutics	$76.0M Series A	—	2xN, 5AM Ventures, Andreessen Horowitz, Angel investor, ARCH Venture Partners, Haun Ventures, Hercules Capital, Highbury Group, Ulu Ventures, What If Ventures, WndrCo LLC
Apr 1, 2022	Tessera Therapeutics	$300.0M Series C	—	Flagship Ventures, Petri
Apr 1, 2022	Prometheus Materials	$8.0M Series A	—	EQT Life Sciences, Illumina Ventures, Kurma Partners, Soffinova Partners
Mar 1, 2022	Deepcell	$73.0M Series B	—	Andreessen Horowitz, Madrona Ventures, Nokia Growth Partners, VZVC

Financial History

Total Raised

N/A

Valuation

N/A

Leadership Team

Key people at Catalio Capital.

Christine E. 'Kricket' Seidman

Venture Partner

Kenan Turnacioglu

General Partner & Member of the Investment Committee

George C. Petrocheilos

Padmanee 'Pam' Sharma

Gordana Vunjak-Novakovic

Nicholas von Guionneau

Analyst

Jeffrey Karp

Venture Partner

Leadership Team

Key people at Catalio Capital.

Christine E. 'Kricket' Seidman

Venture Partner

Kenan Turnacioglu

General Partner & Member of the Investment Committee

George C. Petrocheilos

Padmanee 'Pam' Sharma

Gordana Vunjak-Novakovic

Nicholas von Guionneau

Analyst

Jeffrey Karp

Venture Partner

Deep Dive

High-Level Overview

Catalio Capital Management is a New York-based investment firm specializing in the full lifecycle of innovative healthcare investing, particularly in life sciences and biotechnology. Founded in 2020, it invests across private equity, structured credit, and public equity markets, focusing on breakthrough biomedical technologies and category-defining healthcare companies. Catalio leverages a proprietary network of scientist-entrepreneurs for rigorous scientific due diligence and provides strategic guidance to companies at all stages, from inception to IPO. Its mission centers on supporting transformative healthcare innovations that address unmet medical needs, thereby impacting the startup ecosystem by enabling the growth of pioneering life sciences ventures[1][2][3].

Origin Story

Catalio Capital Management was founded in 2020 in New York City by a team including world-renowned scientist-entrepreneurs and investment professionals. The firm’s leadership includes managing partners and venture partners who are distinguished scientists with proven track records in spinning out and scaling category-defining life sciences companies. This scientific foundation shapes Catalio’s investment philosophy and focus. Over time, the firm has evolved to manage over $1.7 billion in assets and expanded its presence internationally with offices in London and Washington, DC, while maintaining a strong emphasis on biomedical innovation[1][4][5].

Core Differentiators

Unique Investment Model: Catalio invests across the capital structure—private equity, structured credit, and public equities—allowing flexible participation in healthcare innovation at various stages.
Scientific Network Strength: The firm’s proprietary network of scientist-entrepreneurs and venture partners provides deep scientific insight and rigorous due diligence, enhancing investment quality.
Track Record: Managing over $1.7 billion with a portfolio focused on category-defining life sciences companies, Catalio has demonstrated success in identifying and supporting breakthrough biomedical technologies.
Operating Support: Catalio offers strategic guidance to portfolio companies, including recruiting seasoned management teams and advising on clinical and scientific value propositions, leveraging founders who have generated billions in enterprise value[1][2][3][6].

Role in the Broader Tech Landscape

Catalio Capital Management rides the wave of rapid innovation in life sciences and biotechnology, a sector driven by advances in biomedical research, diagnostics, drug development, and healthcare data. The timing is critical as breakthroughs in these areas promise to address significant unmet medical needs and transform healthcare delivery globally. Market forces such as increased healthcare spending, aging populations, and technological convergence favor Catalio’s focus. By investing early and across stages, Catalio influences the broader ecosystem by accelerating the commercialization of disruptive healthcare technologies and fostering a network of scientific entrepreneurs who drive innovation forward[1][2][3][4].

Quick Take & Future Outlook

Looking ahead, Catalio Capital Management is poised to deepen its impact by continuing to back next-generation life sciences companies that push the boundaries of biomedical innovation. Trends such as precision medicine, gene editing, digital health, and AI-driven drug discovery will likely shape its investment focus. As the life sciences sector grows more complex and capital-intensive, Catalio’s scientific expertise and flexible investment approach will be critical in identifying and nurturing transformative healthcare solutions. Its influence is expected to expand as it helps define the future of healthcare innovation and supports companies that could become the next category leaders in biotech and life sciences[1][3][5].

Sources

High-Level Overview

Origin Story

Core Differentiators

Unique Investment Model: Catalio invests across the capital structure—private equity, structured credit, and public equities—allowing flexible participation in healthcare innovation at various stages.
Scientific Network Strength: The firm’s proprietary network of scientist-entrepreneurs and venture partners provides deep scientific insight and rigorous due diligence, enhancing investment quality.
Track Record: Managing over $1.7 billion with a portfolio focused on category-defining life sciences companies, Catalio has demonstrated success in identifying and supporting breakthrough biomedical technologies.
Operating Support: Catalio offers strategic guidance to portfolio companies, including recruiting seasoned management teams and advising on clinical and scientific value propositions, leveraging founders who have generated billions in enterprise value[1][2][3][6].